Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2022
Reporting Period: Second quarter ended June 30, 2022
Business Context: The filing serves as a notification that the company issued a press release on August 9, 2022, reporting its financial results for the second quarter of 2022. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide clear values for these metrics.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that financial results for the quarter were reported in an external press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2022) for actual revenue, net income, and cash flow figures.
- Verify the specific details of the second-quarter results and any year-over-year comparisons in the attached press release.
- Check for any forward-looking statements or guidance included in the press release, as they are not present in this 8-K cover sheet.
- Confirm the trading symbol (HALO) and exchange (The Nasdaq Stock Market LLC) for current market data.